The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
The past and future of haemophilia: diagnosis, treatments, and its complications
Abstract
Haemophilia A and B are hereditary haemorrhagic disorders characterised by deficiency or dysfunction of coagulation protein factors VIII and IX, respectively. Recurrent joint and muscle bleeds lead to severe and progressive musculoskeletal damage. Existing treatment relies on replacement therapy with clotting factors, either at the time of bleeding (ie, on demand) or as part of a prophylactic schedule. The major complication of such therapy is the development of neutralising antibodies (ie, inhibitors), which is most frequent in haemophilia A. Treatment might improve considerably with the availability of new modified drugs, which might overcome existing prophylaxis limitations by reducing dosing frequency and thereby rendering therapy less distressing for the patient. Subcutaneous administration of some new therapies would also simplify prophylaxis in children with poor venous access. Gene therapy has the potential for a definitive cure, and important results have been obtained in haemophilia B. Despite improvements in haemophilia care, the availability of clotting factor concentrates for all affected individuals worldwide remains the biggest challenge.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HA and hemophilia B (HB) are X-linked monogenic disorders resulting from decreased/absent function of coagulation FVIII or FIX.165,166”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [166]
Citations
Cites
Origins and Mechanisms of miRNAs and siRNAs
Carthew, R. W., & Sontheimer, E. J. (2009) · Cell · doi:10.1016/j.cell.2009.01.035 · Cited by 5,018
Presence of fetal DNA in maternal plasma and serum
Lo, Y. M. D., Corbetta, N., Chamberlain, P. F., Rai, V., Sargent, I. L., Redman, C. W., & Wainscoat, J. S. (1997) · The Lancet · doi:10.1016/s0140-6736(97)02174-0 · Cited by 3,129
Keefe, A. D., Pai, S., & Ellington, A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3141 · Cited by 2,289
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067659 · Cited by 1,950
Guidelines for the management of hemophilia
Srivastava, A., Brewer, A. K., Mauser‐Bunschoten, E. P., Key, N. S., Kitchen, S., Llinas, A., Ludlam, C. A., Mahlangu, J. N., Mulder, K., Poon, M. C., et al. (2013) · Haemophilia · doi:10.1111/j.1365-2516.2012.02909.x · Cited by 1,927
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
The hemophilias--from royal genes to gene therapy
Mannucci, P. M., & Tuddenham, E. G. D. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106073442307 · Cited by 1,110
Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B
NILSSON, I. M., BERNTORP, E., LÖFQVIST, T., & PETTERSSON, H. (1992) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1992.tb00546.x · Cited by 961
White, G. C., Rosendaal, F. R., Aledort, L. M., Lusher, J. M., Rothschild, C., & Ingerslev, J. (2001) · PubMed · Cited by 798
Research works printed but not linked: 1
- Shima, 2015, Long-term safety and prophylactic efficacy of once weekly subcutaneous administration of ACE910, in Japanese hemophilia A patients with and without FVIII inhibitors: interim results of the extension study of a phase 1 study, J Thromb Haemost, 13, 6
Cited by
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
“All HA clinical trials use a B-domain-deleted FVIII (BDD-FVIII) transgene, which retains full procoagulant function while meeting AAV packaging constraints ( 4.7 kb) and enhancing expression.187–189 Nearly all HA trials use a standard FVIII B-domain heavy and light chain linker, FVIII-SQ.190 A single trial is using an…”
BackgroundInfluentialNext-generation regulatory T cell therapy
Ferreira, L. M. R., Muller, Y. D., Bluestone, J. A., & Tang, Q. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0041-4 · Cited by 476
Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy
Pasi, K. J., Rangarajan, S., Georgiev, P., Mant, T., Creagh, M. D., Lissitchkov, T., Bevan, D., Austin, S., Hay, C. R., Hegemann, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616569 · Cited by 367
Superhydrophobic hemostatic nanofiber composites for fast clotting and minimal adhesion
Li, Z., Milionis, A., Zheng, Y., Yee, M., Codispoti, L., Tan, F., Poulikakos, D., & Yap, C. H. (2019) · Nature Communications · doi:10.1038/s41467-019-13512-8 · Cited by 329
Systemic delivery of factor IX messenger RNA for protein replacement therapy
Ramaswamy, S., Tonnu, N., Tachikawa, K., Limphong, P., Vega, J. B., Karmali, P. P., Chivukula, P., & Verma, I. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1619653114 · Cited by 301
“They also suffer from recurrent bleeding into joints and muscles, which leads to significant joint pain, deformities, and loss of mobility (7).”
BackgroundMethodInfluential
Metadata
- Authors
- Peyvandi, F., Garagiola, I., & Young, G.
- Affiliations
- University of Milan (IT)
- University of Southern California (US)
- Corresponding author
- Peyvandi, Flora
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2016-07
- Volume
- 388
- Issue
- 10040
- Pages
- 187-197
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2274569134
- Cited by
- 505
- References
- 144
- Citations by year
- 2026: 47 · 2025: 53 · 2024: 57 · 2023: 53 · 2022: 59 · 2021: 60 · 2020: 45 · 2019: 38 · 2018: 37 · 2017: 40 · 2016: 15
- FWCI
- 6.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Keywords
- hemophilia A, hemophilia B, factor replacement therapy, prophylaxis, on-demand treatment, neutralizing antibodies, inhibitors, subcutaneous administration, gene therapy, musculoskeletal damage
- MeSH terms
- Hemophilia B, Coagulants, Factor IX, Factor VIII, Hemophilia A, Hemorrhage, Humans, Genetic Therapy, Antibodies, Neutralizing, Early Medical Intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The past and future of haemophilia: diagnosis, treatments, and its complications. https://app.cochat.ai/papers/10.1016/s0140-6736(15)01123-x
- The paper
- Peyvandi, F., Garagiola, I., & Young, G. (2016). The past and future of haemophilia: diagnosis, treatments, and its complications. The Lancet. https://doi.org/10.1016/s0140-6736(15)01123-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.